


**In the Claims:**

Please replace all previous claim listings with the following claim listing:

1. (currently amended) A method for inhibiting growth of a bacterium which consists essentially of contacting the bacterium with a compound having the structure:



wherein each of  $\text{R}_1$ ,  $\text{R}_2$ ,  $\text{R}_3$ ,  $\text{R}_4$ ,  $\text{R}_5$  and  $\text{R}_6$  comprises independently H, F, Cl, Br, I, -OH, -OR<sub>7</sub>, -CN, -COR<sub>7</sub>, -SR<sub>7</sub>, -N(R<sub>7</sub>)<sub>2</sub>, -NR<sub>7</sub>COR<sub>8</sub>, -NO<sub>2</sub>, -(CH<sub>2</sub>)<sub>p</sub>OR<sub>7</sub>, -(CH<sub>2</sub>)<sub>p</sub>X(R<sub>7</sub>)<sub>2</sub>, -(CH<sub>2</sub>)<sub>p</sub>XR<sub>7</sub>COR<sub>8</sub>, a straight chain or branched, substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, thioalkyl, methylene thioalkyl, acyl, phenyl, substituted phenyl, or heteroaryl; wherein a linkage to the benzene ring may alternatively be -N-, -S-, -O- or -C-; wherein each of R<sub>7</sub> and R<sub>8</sub> may be independently H, F, Cl, Br, I, -OH, -CN, -COH, -SH<sub>2</sub>, -NH<sub>2</sub>, -NHCOH, -(CH<sub>2</sub>)<sub>p</sub>OH, -(CH<sub>2</sub>)<sub>p</sub>X(CH<sub>2</sub>), -(CH<sub>2</sub>)<sub>p</sub>XCOH, a straight chain or branched, substituted or unsubstituted C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, thioalkyl, methylene thioalkyl, acyl, phenyl, substituted phenyl, or heteroaryl; wherein A may be -N<sub>2</sub>-, -NH-, -CH=CH-, -C=C-CH<sub>2</sub>-, -C≡C-CHOH-, -C≡C-CH<sub>2</sub>OH-, -C≡C-CH<sub>2</sub>-, -CH<sub>2</sub>-CH<sub>2</sub>-O-, -CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-O-, -S-, -S(=O)<sub>2</sub>-, -C(=O)-, -C(=O)-O-, -NH-C(=O)-, -C(=O)-NH-, -C=O-,

~~C=O-O-NH-C=O-C=O-NH~~; and wherein Q, p, n and X may independently be an integer from 1 to 10, or if Q is 1 A comprises a (C<sub>1</sub>-C<sub>10</sub>)-alkyl chain, ~~(C<sub>1</sub>-C<sub>10</sub>)~~ ~~-(C<sub>2</sub>-C<sub>10</sub>)-alkenyl~~ chain, ~~-(C<sub>2</sub>-C<sub>10</sub>)-alkylene chain~~, or ~~(C<sub>1</sub>-C<sub>10</sub>)~~ ~~-(C<sub>2</sub>-C<sub>10</sub>)-alkynyl~~ chain which is branched or unbranched, substituted or unsubstituted and can optionally be interrupted 1 to 3 times by -O- or -S- or -N-; or a pharmaceutically acceptable salt or ester thereof, which compound is present in a concentration effective to inhibit growth of the bacterium.

2. (currently amended) The method of claim 1, wherein A comprises an ~~(C<sub>1</sub>-C<sub>10</sub>)~~ ~~-(C<sub>2</sub>-C<sub>10</sub>)-alkylene chain~~, (C<sub>1</sub>-C<sub>10</sub>)-alkyl chain, ~~(C<sub>1</sub>-C<sub>10</sub>)~~ ~~-(C<sub>2</sub>-C<sub>10</sub>)-alkenyl chain~~ or ~~(C<sub>1</sub>-C<sub>10</sub>)~~ ~~-(C<sub>2</sub>-C<sub>10</sub>)-alkynyl chain~~ which is branched or unbranched, substituted or unsubstituted and can optionally be interrupted 1 to 3 times by -O- or -S- or -N-.


3. (original) The method of claim 1, wherein

R<sub>1</sub> = R<sub>4</sub> = CH<sub>3</sub> or -OH,  
R<sub>2</sub> = R<sub>3</sub> = R<sub>5</sub> = R<sub>6</sub> = H or -OH,  
A = CH<sub>2</sub>,  
and Q = 3.


4. (original) The method of claim 1, wherein

R<sub>3</sub> = Cl,  
R<sub>1</sub> = R<sub>2</sub> = R<sub>4</sub> = R<sub>5</sub> = R<sub>6</sub> = H or -OH,  
and Q = 0.

5. (original) The method of claim 1, wherein



6. (original) The method of claim 1, wherein



7. (original) The method of claim 1, wherein the bacterium is *Legionella pneumophila*, *Mycobacterium tuberculosis*, *Bacillus subtilis*, *Bacillus Megaterium*, *Pseudomonas Oleovorans*, *Alcaligenes eutrophus*, *Rhodococcus sp.*, *Citrobacter freundii*, *Group A Streptococcus sp.*, *Coag neg Staphylococcus aureus* or *Nocardia sp.*

8. (original) The method of claim 1, wherein the bacterium is *Legionella pneumophila*.

9. (original) The method of claim 1, wherein the bacterium is *Mycobacterium tuberculosis*.

10. (original) The method of claim 1, wherein the bacterium is in a eukaryotic cell.

11. (original) The method of claim 1, wherein the concentration of the compound is from about 5 µg/ml to about 100 µg/ml.

12. (original) The method of claim 1, wherein the concentration of the compound is 20 µg/ml.

13-59. (canceled).

60. (new) A method for inhibiting growth of a bacterium which consists essentially of contacting the bacterium with gemfibrozil in a concentration effective to inhibit growth of the bacterium.

61. (new) The method of claim 60, wherein the bacterium is *Legionella pneumophila*, *Mycobacterium tuberculosis*, *Bacillus subtilis*, *Bacillus Megaterium*, *Pseudomonas Oleovorans*, *Alcaligenes eutrophus*, *Rhodococcus sp.*, *Citrobacter freundii*, Group A *Streptococcus sp.*, Coag neg *Staphylococcus aureus* or *Nocardia sp.*

62. (new) The method of claim 60, wherein the bacterium is *Legionella pneumophila*.

63. (new) The method of claim 60, wherein the bacterium is *Mycobacterium tuberculosis*.

64. (new) The method of claim 60, wherein the bacterium is in a eukaryotic cell.

65. (new) The method of claim 60, wherein the concentration of gemfibrozil is from about 5 µg/ml to about 100 µg/ml.

Applicants: Christina Kabbash et al.  
U.S. Serial No.: 10/813,322  
Filed: March 29, 2004  
Page 6

66. (new) The method of claim 60, wherein the concentration of gemfibrozil is 20 µg/ml.

67. (new) A method for alleviating the symptoms of a bacterial infection in a subject which consists essentially of administering to the subject an amount of gemfibrozil in a concentration effective to inhibit bacterial growth and thus alleviate the symptoms of the bacterial infection in the subject.

68. (new) The method of claim 67, wherein the bacterial infection is associated with *Legionella pneumophila*, *Mycobacterium tuberculosis*, *Bacillus subtilis*, *Bacillus Megaterium*, *Pseudomonas Oleovorans*, *Alcaligenes eutrophus*, *Rhodococcus sp.*, *Citrobacter freundii*, Group A *Streptococcus sp.*, Coag neg *Staphylococcus aureus* or *Nocardia sp.*

69. (new) The method of claim 67, wherein the bacterial infection is associated with *Legionella pneumophila*.

70. (new) The method of claim 67, wherein the bacterial infection is associated with *Mycobacterium tuberculosis*.

71. (new) The method of claim 67, wherein the subject is a human or an animal.

72. (new) The method of claim 67, wherein the bacterial infection is associated with Leprosy, *Brucella* or *Salmonella*.

73. (new) The method of claim 67, wherein the concentration of gemfibrozil is from about 5 µg/ml blood of the subject to about 180 µg/ml blood of the subject.

74. (new) The method of claim 67, wherein the concentration of gemfibrozil is 90 µg/ml blood of the subject.

75. (new) The method of claim 67, wherein the administration to the subject is oral.

76. (new) A method of altering a pathway of fatty acid synthesis in a bacterium which comprises contacting the bacterium with gemfibrozil thus altering the pathway of fatty acid synthesis.

77. (new) The method of claim 76, wherein the bacterium is *Legionella pneumophila*, *Mycobacterium tuberculosis*, *Bacillus subtilis*, *Bacillus Megaterium*, *Pseudomonas Oleovorans*, *Alcaligenes eutrophus*, *Rhodococcus sp.*, *Citrobacter freundii*, Group A *Streptococcus sp.*, *Coag neg Staphylococcus aureus* or *Nocardia sp.*

78. (new) A method for determining whether or not a bacterium is sensitive to gemfibrozil which comprises contacting the bacterium with a concentration of gemfibrozil effective to inhibit growth of the bacterium if the bacterium is sensitive to gemfibrozil, thereby determining whether or not the bacterium is sensitive to the gemfibrozil.

79. (new) The method of claim 78, wherein the bacterium is in a cell.

80. (new) The method of claim 78, wherein the bacterium is selected from the group consisting of *Legionella pneumophila*, *Bacillus subtilis*, *Caulobacter crescentus*,

Applicants: Christina Kabbash et al.

U.S. Serial No.: 10/813,322

Filed: March 29, 2004

Page 8

*Citrobacter freundii*, *Nocardia* sp., *Rhodobacter spheroides*,  
Group A *Streptococcus* sp., Coag neg *Staphylococcus aureus*  
and *Mycobacterium tuberculosis*.

81. (new) The method of claim 78, wherein the concentration of the  
gemfibrozil is from about 5µg/ml to about 100µg/ml.

82. (new) The method of claim 78, wherein the concentration of the  
gemfibrozil is 20 µg/ml.